Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05983432 · ClinicalTrials.gov registry record · Phase 1
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by SystImmune.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 470
- Enrollment target
- 20
- Study locations
NCT05983432 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by SystImmune. The registered enrollment target is 470 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05983432, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by SystImmune.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 470 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Conditions Studied
Interventions
- DRUG BL-B01D1
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- City of Hope Cancer Center - Duarte
- Chao Family Comprehensive Cancer Care and Ambulatory Care - Irvine
- Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- University of California Irvine Medical Center - Orange
- UCLA Santa Monica - Santa Monica
Florida
- Sylvester Comprehensive Cancer Center - Miami
- Sara Cannon Research Institute Lake Nona - Orlando
- Hematology - Oncology Associates of the Treasure Coast - Port Saint Lucie
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Colorado
- University of Colorado Cancer Center - Aurora
Connecticut
- Yale University, Yale Cancer Center - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2023-08-08 |
| Est. Completion | 2028-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05983432
The ClinicalTrials.gov registry entry for NCT05983432 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (83% lower). The listed sponsor is SystImmune, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which BL-B01D1 is the first listed.
NCT05983432 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05983432 about?
NCT05983432 is a clinical study titled "Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors". The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
What is the current status of trial NCT05983432?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 470 participants. The study started on 2023-08-08. Estimated completion is 2028-03-21.
What conditions does trial NCT05983432 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Ovarian Cancer, Endometrial Cancer.
What interventions are being tested in trial NCT05983432?
The interventions under investigation include: BL-B01D1 (DRUG).
Who is sponsoring clinical trial NCT05983432?
This trial is sponsored by SystImmune, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05983432 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.